N/A N=14 The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis
RheumatoId Arthritis
Primary: Sleep Quality - Trouble Falling Asleep, 6 Weeks — 1.3 score on a scale — p=0.10
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=120 Effect of Intraoperative Dexmedetomidine on Early Postoperative Cognitive Dysfunction
Cognitive Dysfunction
Primary: Number of Cases Developing POCD — 10; 21 Participants
Phase 3 N=63 Blinded Trial of Buprenorphine or Morphine in the Treatment of the Neonatal Abstinence Syndrome
Neonatal Abstinence Syndrome
Primary: Length of Treatment — 15; 28 days — p=<0.05
Phase 1 N=103 STP206 for the Prevention of Necrotizing Enterocolitis (NEC)
Necrotizing Enterocolitis
Primary: Number and Severity of Adverse Events Experienced by Subjects in Low-dose Treatment Groups — 7; 4; 7; 3 Participants
Phase 2 N=75 Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Parkinson Disease
Primary: Unified Dyskinesia Rating Scale (UDysRS) — -4.2; -7.0 score on a scale
N/A N=1,153 Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi
Tuberculosis
Primary: Proportion of Cases Successfully Treated, Defined as the Total Number of Cases Cured and Completing Treatment. — 297; 348 Participants
N/A N=36 Reliability of Consumer Sleep Trackers in Patients Suffering From Obstructive Sleep Apnea Syndrome
Obstructive Sleep Apnea Syndrome
Primary: Time in Bed — 519; 446; 522; 524 min
N/A N=41 Hip Osteoarthritis: Effects of Exercise Programs on Pain and Disability
Hip Osteoarthritis
Primary: Change in 6-minute Walk Test — 22; 49 meters
Early Phase 1 N=42 Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibody Response After a Single Dose of Tdap in Pregnant Thai Women
Pertussis · Pregnancy Related
Primary: The Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG) in Pregnant Thai Women — 43 Participants
Phase 3 N=140 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia
Dyslipidemia
Primary: Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment — -48.2; -43.6; -42.0; 2.6 percent change
Phase 2 N=17 Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa
Hidradenitis Suppurativa · Hidradenitis · Acne Inversa
Primary: Change in Disease Severity — 23.3; 17.7 score on a scale — p=0.042
Phase 2 N=1,131 A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors
Primary: Objective Response Rate ( ORR ) — 5.6; 0.0; 0.0; 11.9 Percentage of Participants — p=0.0309
Phase 3 N=25 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus
Interstitial Pneumonitis · Polymyositis · Dermatomyositis
Primary: Overall Survival — 88.0 percentage of participants
Phase 2 N=160 Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries
Hereditary Breast and Ovarian Cancer Syndrome · Osteoporosis · Ovarian Carcinoma
Primary: Bone Mineral Density of the Lumbar Spine as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan at 9 Months — -0.025; -0.086 g/cm2
Phase 1 N=89 A Study of LY2228820 in Participants With Advanced Cancer
Advanced Cancer
Primary: Number of Participants With Clinically Significant Effects (Physical Assessments and Safety Lab Tests) — 1; 3; 2; 3 Participants